{"name":"Novan, Inc.","slug":"novan-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SB204 4%","genericName":"SB204 4%","slug":"sb204-4","indication":"Acne vulgaris","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"SB206 10.3% berdazimer","genericName":"SB206 10.3% berdazimer","slug":"sb206-10-3-berdazimer","indication":"Molluscum contagiosum (topical treatment)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"SB206 12%","genericName":"SB206 12%","slug":"sb206-12","indication":"Molluscum contagiosum","status":"phase_3"}]}],"pipeline":[{"name":"SB204 4%","genericName":"SB204 4%","slug":"sb204-4","phase":"phase_3","mechanism":"SB204 4% is a topical nitric oxide-releasing agent.","indications":["Acne vulgaris"],"catalyst":""},{"name":"SB206 10.3% berdazimer","genericName":"SB206 10.3% berdazimer","slug":"sb206-10-3-berdazimer","phase":"phase_3","mechanism":"Berdazimer is a nitric oxide-releasing topical agent that generates nitric oxide to exert antimicrobial and anti-inflammatory effects on skin lesions.","indications":["Molluscum contagiosum (topical treatment)","Other viral skin infections"],"catalyst":""},{"name":"SB206 12%","genericName":"SB206 12%","slug":"sb206-12","phase":"phase_3","mechanism":"SB206 is a nitric oxide-releasing topical agent that delivers nitric oxide to skin lesions to promote healing and reduce bacterial burden.","indications":["Molluscum contagiosum","Warts"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQWDc2akxaYnp1UG5jQmY5RkFjaXhXX2dJWDZyWlBoODd4TFZLRS04MWo2bXhDM3M2bnFXbUN6aVpjUzkwU19kazJSbjJ1UDhvMWlkWDZDY0NwOWkyZWw0ZHdMNnNPRlUtdEtQTENNUzZFT2ZQcVhEUWxpcVg1dC1uSjNTQ2FUSGxFXzVReDhycU5xZGMwTGhia1RCemdKMDlWb2NBMTUyNmZKQkl0ZFB6YkJlVWhkS2FwVEFoZHNPdkhULURBZnpRLWRTVF9PQ1lNenZRci1Fdw?oc=5","date":"2026-03-31","type":"pipeline","source":"Sahm","summary":"FOCUS-Drugmakers delay some European launches with a wary eye on Trump's pricing policies - Sahm","headline":"FOCUS-Drugmakers delay some European launches with a wary eye on Trump's pricing policies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQdlFxeEQ0eklHNXJXYUxxUzRpdzdITDZtTTd2cjRUTW0zbTQ3eEEzWXVZRnNWenVYM2xMVFFlQ3o4dWNfNnNIQUdUZHNTVTNrUnpZOEZwaW92ZmJIZ2pyeEwyTG1vS19KN084V2xQemNMTGxfT2tnNnhyY19jVmx6bl9tN1dxVkhjbEY2QW5ocmMzWi0zZkdjaXVobnVyZDFrdlUyWllNRjBQQ0RiR1lKMUJWOWstTnZkaFZDQUVaVVlFRXV3?oc=5","date":"2025-04-17","type":"deal","source":"Fierce Pharma","summary":"Ligand's Pelthos unit joins forces with Channel Therapeutics in merger centered on launch of molluscum gel Zelsuvmi - Fierce Pharma","headline":"Ligand's Pelthos unit joins forces with Channel Therapeutics in merger centered on launch of molluscum gel Zelsuvmi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQNG9zc0pNVXZpQ0JBSXRRMlFDX0JGWW93cXEwLUY4MXlaSWkwZXphd2VhUGNIUm1fcnY3elJlWFpDNHpfQTliaENLbV9tWk1OeC1fbGQtTzFKTmdUaWt1NWNHbjRjRldlblVGZU1EMXBlNllIRzZRdUNZOTFEb2g3WHhIZDN5WkhsSGhTWHRKcGZDNHdUUWZZU3hROURiNGdBdjZCRlY3bnpCeGpBTm5rWWo5Yw?oc=5","date":"2025-03-21","type":"deal","source":"businesswire.com","summary":"Ligand Acquires Assets of Novan, Inc. for $12.2 Million - businesswire.com","headline":"Ligand Acquires Assets of Novan, Inc. for $12.2 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxONW43WDVOaFhjOGRYWDRKV2w0NlJqSVlpVDMySVdHVExTVkg5NVFmc1c2VEkzZFM4YkJsNDJLT09WUGRFSG5qNzhYVF9ETVJsQzJlYVpqcE5QNWNqcmk3T2hncjBpdEI3X1NEc1VHZmdFQ3cwU01Qb2I0MzZyZEt1Yi1kdlVXRVpGQlJyM1pNZXJ0Zkd0SHN1ZVJTVDZQQmRZUVpkUjZVYlVfMG8?oc=5","date":"2024-04-04","type":"pipeline","source":"The Business Journals","summary":"Novan is gone. But its lead drug lives on with new company - The Business Journals","headline":"Novan is gone. But its lead drug lives on with new company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPakdONDhfMUl5MU8yQlVtU2stUXI5WkFGTGZrVjhzR3Q1Y2pJdlhUNmdzWEJodHNCcmxFVkppNFR4Z0tnVHdWZjdNcVF5THRwY2J0c0lseWRKUDY4bFRHNzlDa0VLanh0MTRxMGtvdk4wYXBEVXBaSTNxTlp5Q0RzNUVKekkwUGhGQ3R4LWF1N3QzUmpBYjk0ZkN0S1cyZGd0aklrTm41S3M4aHhpQUZnUE1IYnJacFlXNTZlSGpDZ1J3Wnl1ZjRIR21PZmQ?oc=5","date":"2024-04-03","type":"pipeline","source":"BioSpace","summary":"Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI - BioSpace","headline":"Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPTXplNHF6Y3RTNmY2UVc4eTJRMnFINTRNSnF2aGpkLVQxcFNidlhMMFhJYmR2aDN4UnNMaUxBbkxMVFRKVFk0VzQ3UFJIVlY3MmpnYUlyb3dnNzJITy0xRjMtcUUxZXI2aEVyWXdsZGoyQ2lOTXhNOWJKaTNHVTBwSjJGZ19TUHRxSk9McTBIbkRUR3doQjBST292YVNWN3o5MXBQeHc4Q3UxSHo2RzJCNEdCQ0NKX3c?oc=5","date":"2024-01-07","type":"regulatory","source":"Fierce Pharma","summary":"After buying Novan's assets, Ligand crosses FDA finish line with molluscum gel Zelsuvmi - Fierce Pharma","headline":"After buying Novan's assets, Ligand crosses FDA finish line with molluscum gel Zelsuvmi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPOGhYdXVhaTVtMENUTFVMcGowX18ycmlDa05SbkVxa05Dd2RtSkJKRHZjUGx2WHFkSWFvZlIxbFNfZTFwRTNhal80QXQ4U2pBUWZrX0d6Y1BxakRiTnNwekw5U3pSUHdWSTgyMnlMdGctYjh0Y2V1OU9CNnpRYTd1aWxpVTlqellmeUI0?oc=5","date":"2023-11-02","type":"pipeline","source":"Pharma Voice","summary":"In a record year for biotech bankruptcy, here are 3 companies that went under - Pharma Voice","headline":"In a record year for biotech bankruptcy, here are 3 companies that went under","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9sT2ZUTWFhamhETlB4VHJYX1RBaEtCMy1iRF8wR1Y4U0pCakg5VXluUjFhTWpkTjEtUzZnZnNhQVk2eGRiVU96aDFoeVhoUnBrWTRuLWJ6YUVOSUlDYVhWb25PbGxUOXNJWENrb3U5VnozQmxEVDVBUnM3a1Q?oc=5","date":"2023-09-12","type":"pipeline","source":"Financier Worldwide","summary":"Novan files for Chapter 11 bankruptcy - Financier Worldwide","headline":"Novan files for Chapter 11 bankruptcy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQaDVEM045WjF3dXFsRmxIRDVxN2RJNHc0NHdJUzE1WURsQmhJNThPLXJjWWhTX0tScGNOY1owSGZGaGFwUndvVXpfMFhURWh4amdOMk1QU2NhbFdpQWZUcWVuaHhEV1VWQmF5dEVkY3MwUF9hVzEtYTJiY2pfeHE0NkJldTV1QlVXSkd6OU5XT0NNaVVYRVVmLQ?oc=5","date":"2023-07-18","type":"pipeline","source":"Carolina Journal","summary":"Durham-based Novan Inc. sells all assets, files for bankruptcy - Carolina Journal","headline":"Durham-based Novan Inc. sells all assets, files for bankruptcy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNS2VhWDV1YjdMMGJlWTgxQzZEbjV4WVVSSU9KUnRTVllCUDctS1B1X2pBWHNEM2VkVlk3S1FZbG0ySDNaV0ZoUV9ZTXlYWVdhb1hHNUN1ZGxoN1pzVWthTTl4aWc3YjVpSGJpXzhSckZ6clF0dW9ERjBxY3dHbnl0UHpldFByR21pT0J1NnFoMDlmTGNMWUFseG5hRXZFVkI0V2dj?oc=5","date":"2023-07-17","type":"pipeline","source":"Dermatology Times","summary":"Novan Inc to Sell All Assets and File for Chapter 11 Protection - Dermatology Times","headline":"Novan Inc to Sell All Assets and File for Chapter 11 Protection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE5FdnZFWWlCOWo1QWE2U2w1Mng1SWFiOVFiZ2xDUVRxM21ocnVZQ1JIWXVaLVIxcDhCVlVCNDRJZlNaZE9Pd2ozZWFRLW9CeVVJcHREZVJCX3J0VE5FQkdsUHg0bUpfOXpOMThGUk1iX3plZw?oc=5","date":"2023-07-17","type":"deal","source":"Raleigh News & Observer","summary":"Durham dermatology company files for bankruptcy and reaches deal for sale - Raleigh News & Observer","headline":"Durham dermatology company files for bankruptcy and reaches deal for sale - Raleigh News & Observer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE16NGhSWWw1c3VPOGpmMmM5bUN4X3pLLWNsVzRfYmtISWNjUkdudnZWclZCZzJaU05LN3JkSlUtTWllazVPWEtvN25YZFJlVmdjNEFmeDQyTFhzUHlRSk9j?oc=5","date":"2020-01-21","type":"pipeline","source":"ChartMill","summary":"NOVN Stock Price, Quote & Chart | NOVAN INC (NASDAQ:NOVN) - ChartMill","headline":"NOVN Stock Price, Quote & Chart | NOVAN INC (NASDAQ:NOVN)","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}